Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported equity awards consisting of new options and restricted stock units tied to ordinary shares. The filing shows a grant of share options to purchase 142,216 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. A separate award granted 97,536 ordinary shares in the form of restricted stock units, with 25% of both the RSUs and options vesting on April 2, 2027 and the remainder vesting in installments through April 2, 2030. After these awards, Van Well is shown as beneficially owning 358,774 ordinary shares. This Form 4/A amends a prior report to correct the post-transaction ordinary share balance, which had been understated.
SOPHiA GENETICS SA President Ross Muken received new equity awards and corrected his reported share holdings. On April 2, 2026 he was granted options to buy 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.
He also received 431,211 restricted stock units, each representing one ordinary share, bringing his directly held ordinary shares to 703,121 after the grant. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.
The share options vest 25% on April 2, 2027 and then in equal monthly installments through April 2, 2030. This amended filing corrects a prior report that had understated his post-transaction ordinary share holdings.
CARDOZA GEORGE reported acquisition or exercise transactions in this Form 4 filing.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza received new equity awards and corrected a prior ownership figure. On April 2, 2026 he was granted options to buy 164,671 ordinary shares at $5.04 per share, vesting 25% on April 2, 2027 and then monthly through April 2, 2030. He also received 112,936 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. After these awards, he beneficially owns 297,794 ordinary shares directly, correcting a previously reported amount of 112,936 shares that was described as an inadvertent error.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported awards of share-based incentives and corrected his reported holdings. He received a share option for 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.
He was also granted 431,211 restricted stock units, each representing one ordinary share, under the 2021 Equity Incentive Plan. Following these grants, his beneficially owned ordinary shares are correctly reported as 3,734,050, revising a previously misstated amount in an earlier Form 4.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported equity compensation grants consisting of options and restricted stock units tied to ordinary shares. He received a share option covering 164,671 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 112,936 RSUs, each representing one ordinary share, vesting 25% on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. Following these grants, his beneficial ownership of ordinary shares was corrected to 286,552 shares due to an earlier inadvertent reporting error.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity compensation awards and corrected prior ownership data. He received a grant of 82,335 share options with a $5.04 exercise price expiring on April 2, 2036, plus 56,468 RSUs. The Form 4/A updates his beneficial ownership to 148,854 ordinary shares after these awards, amending an earlier filing that understated this amount.
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings. She was granted an option for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. Following these awards and a correction to a prior report, her directly held ordinary shares are reported as 224,248.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported equity compensation grants and a correction to his reported holdings. He received a share option for 164,671 ordinary shares at an exercise price of $5.04 per share and a grant of 112,936 ordinary shares in the form of restricted stock units under the 2021 Equity Incentive Plan. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. The amendment corrects his beneficial ownership after the transactions to 650,052 ordinary shares, instead of 112,936 shares previously reported due to an inadvertent error.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported equity awards and a correction to his reported holdings. He received a share option for 119,760 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036, and 82,136 restricted stock units representing future ordinary shares.
The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The amendment also corrects his ordinary share holdings after the reported transactions to 207,949 shares, instead of 82,136 shares previously reported due to an error.
Morgan Stanley Smith Barney LLC filed a Form 144 for SOPH listing 20,689 Restricted Stock Units of Common Stock to be sold on 04/02/2026. The filing also records three 10b5-1 sales by ROSS J MUKEN: 1,183 shares on 03/19/2026 for $5,670.95, and 760 shares on 02/19/2026 and 01/20/2026 for $3,665.94 and $4,077.78, respectively.